The phase 2 FLIGHT-FXR trial (NCT02855164) assessed its impact in MASH patients, revealing significant reductions in ALT and GGT levels, body weight, and the MRI-estimated proton density fat fraction (MRI-PDFF) over 48 weeks [122,123]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.